Clinical trials: Advanced Intestinal Cancer
Rectal Cancer, Adenocarcinoma
SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC
This is a single-center, exploratory clinical study for patients with newly diagnosed, high-risk, locally advanced rectal cancer.
- Trial name
- NCT07474103
- Testing
- SCRT, Liposomal Irinotecan, Oxaliplatin
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Colorectal Adenocarcinoma
Oncological Impact of Lateral Nodes in Rectal Cancer
The combination of neoadjuvant chemoradiotherapy (CRT) and total mesorectal excision (TME) is considered the standard treatment for locally advanced rectal cancer in the western world.
- Trial name
- I-ONARC (NCT05592873)
- Testing
- Neoadjuvant chemoradiotherapy (CRT)
- Volunteers
- 317 people
- Sponsor
- Niguarda Hospital
Colorectal Cancer
Gene Expression in Patients With Advanced or Metastatic Colorectal Cancer Receiving Bevacizumab
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897754
- Testing
- gene expression analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction
- Volunteers
- 200 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Stage IV Colorectal Cancer, Gastric Cancer
Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients
The purpose of this study is to investigate the association between UGT1A1 polymorphisms and neutropenia and diarrhea in Korean patients with advanced colorectal or gastric cancer treated with FOLFIRI regimen.
- Trial name
- NCT01271582
- Testing
- Irinotecan, 5FU, leucovorin
- Where
- 5 sites in South Korea
- Volunteers
- 1,500 people
- Sponsor
- Asan Medical Center
Colon Cancer (Stage II &Amp;Amp; III)
mFOLFOXIRI Plus PD-1 Inhibitor vs mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced Colon Cancer
In patients with high-risk stage II and stage III colon cancer, curative surgery followed by adjuvant chemotherapy with FOLFOX or CAPOX regimens has become the standard treatment.
- Trial name
- OPTICAL-3 (NCT06890624)
- Testing
- cmFOLFOXIRI plus PD-1 inhibitor, mFOLFOX6
- Volunteers
- 138 people
- Sponsor
- Sun Yat-sen University
Advanced Solid Tumor
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors.
- Trial name
- NCT07749586
- Testing
- ARV-6723, Pembrolizumab, SOC
- Where
- 4 sites in United States
- Volunteers
- 499 people
- Sponsor
- Arvinas Inc.
Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Rectum
Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Rectal Cancer
Phase I trial to study the effectiveness of radiation therapy plus chemotherapy followed by surgery and additional chemotherapy in treating patients who have advanced nonmetastatic primary cancer of the rectum.
- Conditions
- Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer
- Trial name
- NCT00003799
- Testing
- fluorouracil, oxaliplatin, radiation therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Cancer
Preoperative Panitumumab and Radiotherapy in Rectal Cancer
The purpose of this study is to investigate the activity of panitumumab in combination with standard preoperative radiotherapy in locally advanced rectal cancer, followed by complete surgery and adjuvant chemotherapy.
- Trial name
- PrePaRad (NCT00973193)
- Testing
- panitumumab
- Where
- 8 sites in Belgium
- Volunteers
- 20 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Anal Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003652
- Testing
- cisplatin, fluorouracil, neoadjuvant therapy
- Where
- 48 sites in France
- Volunteers
- 350 people
- Sponsor
- UNICANCER
Advanced Solid Tumors, Breast Cancer Recurrent
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
The goal of this study is to identify a safe and tolerated dose of the orally administered DHX9 inhibitor ATX-559. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of…
- Conditions
- Advanced Solid Tumors, Breast Cancer Recurrent, Colorectal Cancer Metastatic, Colon Cancer
- Trial name
- NCT06625515
- Testing
- ATX-559
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Accent Therapeutics
Colorectal Cancer
A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer
This study will evaluate the safety, tolerability, and pharmacokinetics of BLYG8824A and will make a preliminary assessment of the anti-tumor activity of BLYG8824A in patients with locally advanced or metastatic colorectal cancer.
- Trial name
- NCT04468607
- Testing
- BLYG8824A
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 46 people
- Sponsor
- Genentech, Inc.
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
Randomized phase III trial to compare the effectiveness of irinotecan with that of combination chemotherapy in treating patients who have advanced colorectal cancer that has not responded to previous treatment.
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00005036
- Testing
- irinotecan hydrochloride, oxaliplatin, leucovorin calcium
- Where
- United States
- Volunteers
- 560 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI
The primary endpoint is to evaluate the progression-free survival (PFS).
- Trial name
- NCT04833036
- Testing
- Irinotecan, cetuximab
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fudan University
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Colorectal Cancer
Radiation Therapy and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Patients With Rectal Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00021398
- Testing
- fluorouracil, leucovorin calcium, conventional surgery
- Where
- 17 sites in United States
- Volunteers
- 23 people
- Sponsor
- Fox Chase Cancer Center
Rectal Cancer
Neoadjuvant Chemoradiation With 5-FU(or Capecitabine) and Oxaliplatin Combined With Hyperthermia in Rectal Cancer
This trial examines the feasibility, effectiveness and safety of a combination of radiotherapy (over a period of five weeks) and chemotherapy (with 5-FU or Capecitabine and Oxaliplatin) and 10 fractions of deep regional…
- Trial name
- HyRec (NCT01716949)
- Testing
- Radiotherapy, Hyperthermia, 5-Fluorouracil
- Where
- 6 sites in Germany
- Volunteers
- 59 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Chronic Myeloproliferative Disorders, Leukemia
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
RATIONALE: Antiemetic drugs, such as ondansetron, may help to reduce or prevent nausea and vomiting in patients with advanced cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006348
- Testing
- ondansetron
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative
- Trial name
- DUET-3 (NCT03752398)
- Testing
- XmAb®23104, Yervoy® (ipilimumab)
- Where
- 18 sites in United States
- Volunteers
- 198 people
- Sponsor
- Xencor, Inc.
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
This study is open to adult patients with solid tumors who have a KRAS G12V mutation. This mutation is often found in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and other…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor
- Trial name
- NCT06105021
- Testing
- AFNT-211
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Affini-T Therapeutics, Inc.
Microscopic Colitis, Colorectal Cancer
Mucosa Adherent Intestinal Microbiome in Microscopic Colitis and Colorectal Cancer
Microscopic colitis (MC) is an inflammatory bowel disease characterized by chronic non-bloody watery diarrhoea and a macroscopically normal colonic mucosa upon endoscopic exploration (colonoscopy).
- Conditions
- Microscopic Colitis, Colorectal Cancer, Colon Adenoma
- Trial name
- CMBACT (NCT06172647)
- Testing
- Colonoscopy
- Where
- Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hospital Mutua de Terrassa
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.